Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.

May 23, 2025 · Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 gene mutations. Includes Enhertu side effects, uses, package insert and more.

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to …

Jun 1, 2025 · Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) is a targeted therapy called an antibody-drug conjugate (ADC). ADCs target specific proteins found on the surface …

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ENHERTU safely and effectively. See full prescribing information …

Discover ENHERTU, an FDA-approved treatment option. See Prescribing Information, including Boxed WARNINGS.

Enhertu® (fam-trastuzumab deruxtecan-nxki) intravenous (I.V.) infusion over 90 minutes on Day 1 If the 90-minute infusion is well tolerated, subsequent infusions may be given over 30 minutes …

Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, …

Jan 31, 2025 · Enhertu (fam-trastuzumab deruxtecan-nxki) is commonly used for treating different kinds of HER2-positive solid tumors, including certain types of breast cancer, non-small cell …

Aug 28, 2024 · Enhertu (fam-trastuzumab deruxtecan-nxki*) is a prescription drug used to treat certain kinds of cancer, including breast cancer. Enhertu is given by intravenous infusion (an …